Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA

Abstract

ObjectivesEffective oral therapies for hepatitis B and C have recently been developed, while there are no approved pharmacological therapies for alcoholic and non-alcoholic fatty liver diseases (ALD and NAFLD). We hypothesise that fewer advances in fatty liver diseases could be related to disparities in research attention.MethodsWe developed the Attention-to-Burden Index (ABI) that compares the research activities during 2010–2014, and an estimate of disease burden of these 4 major liver diseases. The resulting ratio reflects either overattention (positive value) or inadequate attention (negative value) compared with disease burden. The mean research attention and disease burden were calculated from 5 and 6 different parameters, respectively. The efficacy rate of current pharmacological therapies was assessed from published clinical trials.FindingsThe mean research attention for hepatitis B and C was 31% and 47%, respectively, while NAFLD and ALD received 17% and 5%. The overall burden was 5% and 28% for hepatitis B and C, and 17% and 50% for NAFLD and ALD. The calculated ABI for hepatitis B and C revealed a +6.7-fold and +1.7-fold overattention, respectively. NAFLD received an appropriate attention compared with its burden, while ALD received marked inadequate attention of −9.7-fold. The efficacy rate of current pharmacological agents was 72% for hepatitis B, 89% for hepatitis C, 25% for non-alcoholic steatohepatitis and 13% for alcoholic hepatitis. Importantly, we found a positive correlation between the mean attention and the efficacy rate of current therapies in these 4 major liver diseases.InterpretationThere are important disparities between research attention and disease burden among the major liver diseases. While viral hepatitis has received considerable attention, there is a marked inadequate attention to ALD. There is a critical need to increase awareness of ALD in the liver research community.

Colder Weather and Fewer Sunlight Hours Increase Alcohol Consumption and Alcoholic Cirrhosis Worldwide

“…It is not surprising that the burden of liver diseases as a cause of mortality is steadily increasing . We recently demonstrated that alcohol receives scant attention by the liver research community compared with other etiologies, such as viral hepatitis . Identifying the main determinants of excessive alcohol consumption at a global scale can favor preventive measures at the public health level.…”

Public health policies and alcohol-related liver disease

“…10 Despite this huge health and economic burden, ALD has received scarce attention compared to other types of liver disease. 11 Although the amount of alcohol intake influences its deleterious consequences, a precise threshold that is associated with increased morbidity and mortality is unclear. A recent study has shown that even low doses of alcohol intake, historically considered as protective, increase allcause mortality.…”

Propranolol Is Associated with Lower Risk of Incidence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Tertiary-Center Study and Indirect Comparison with Meta-Analysis

“…Despite the substantial proportion and enormous disease burden of AC, less research attention has been paid to it than to other etiologies such as viral hepatitis and nonalcoholic fatty liver disease [31]. Except for the well-known prognostic benefits of NSBB including propranolol for cirrhotic patients with portal hypertension, in patients with AC and alcoholic cardiomyopathy or congestive heart failure, NSBB improves quality of life, hemodynamics, and ejection fraction and reduces the severity of pulmonary hypertension [32,33].…”